For Authors
Instructions for authors
Contents
- Manuscript Submission
- Disclosure of Conflicts of Interest
- Research Ethics, Ethics Approval, and Informed Consent
- Reporting Guidelines and Trial Registration
- Consent for Publication and Patient Privacy
- Previous Publication or Duplicate Submission
- Basic Criteria
- Article Categories
- Manuscript Preparation
- The Editorial and Peer Review Process
- Preparation for Publication
- Publication criteria
BioMedicine is a peer-reviewed, open access quarterly journal that publishes high-quality scientific research in precision medicine and related areas, including clinical, laboratory, biological, and health research. The journal publishes in English using American spelling. Publication in BioMedicine is free of charge for authors, and published articles are made available on an open access basis under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.
Authors should ensure that their manuscript is within the journal’s Aims and Scope and complies with these Instructions for Authors, the journal’s Policies and Ethics page, and all requirements of the online submission system. Submissions that are incomplete or do not follow the journal’s requirements may be returned to authors before editorial review.
1. Manuscript Submission
Manuscripts must be submitted through the journal’s online manuscript submission and editorial system. Authors must follow all instructions provided in the submission system and upload all required files and supporting documents.
Submission system: Editorial Manager (https://www.editorialmanager.com/bmdcn/default1.aspx) Editorial Office, BioMedicine No. 91, Hsueh-Shih Road, Taichung 40402, Taiwan Tel: (+886) 4-22070672 Email: [email protected]
1.1. Important Information
Articles should be submitted in Microsoft Word format and prepared as simply as possible. The publisher will apply the journal’s house style during production.
BioMedicine uses a double-blind peer review process. Authors must therefore prepare and upload separate files as described below:
- Blinded manuscript file: this file should contain the manuscript title, abstract, main text, references, tables, and figure legends as appropriate, but must not contain author names, affiliations, acknowledgments, or other author-identifying information. Any declaration or statement that would identify the authors or their institutions should be provided separately during review and included in the final accepted manuscript for publication.
- Title page file: this file should contain the manuscript title, full author names, affiliations, corresponding author information, acknowledgments, and any author-identifying information or declarations that should not appear in the blinded manuscript file.
Authors must check all uploaded files CAREfully to ensure that the blinded manuscript does not contain author-identifying details in the text, file name, acknowledgments, declarations, or document properties.
1.2. Supporting Documents
Authors must provide the following materials according to the manuscript type, study design, and manuscript content. Authors must also complete all mandatory forms and declarations presented in the Editorial Manager submission system:
- Cover letter, including the manuscript title and corresponding author contact information.
- Title page file with full author information and any author-identifying statements that should be excluded from the blinded manuscript.
- Blinded manuscript file prepared for double-blind peer review.
- Authorship confirmation, completed in Editorial Manager as part of the submission process. No separate signed Authorship Statement is required.
- Conflict of Interest Statement. Authors must also include a separate Conflict of Interest statement in the manuscript.
- License confirmation, completed directly in Editorial Manager. BioMedicine publishes articles under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. Authors retain copyright and agree during submission that the manuscript, if accepted, will be published under CC BY 4.0.
- Ethics approval documentation for manuscripts reporting studies involving human participants, human data, human tissue, animals, or other ethically sensitive materials.
- CONSORT flow chart and any other required reporting materials for randomized controlled trials.
- CARE Checklist for case reports.
- Confirmation of consent for publication for all case reports and for any manuscript containing identifiable patient material, images, or case details.
- Written permission for any reproduced or adapted third-party material unless the material is in the public domain or covered by a license that permits the intended reuse.
- Required statements and declarations in accordance with the “Statements and Declarations” section below, including Funding and Conflict of Interest statements for all submissions; Author Contributions for Original Articles, Review Articles, Case Reports, and Short Communications; Data Availability for original research articles and Short Communications reporting original research; ethics and consent statements for relevant studies or article types; and an AI Use Declaration when substantive generative AI or AI-assisted technologies were used.
2. Disclosure of Conflicts of Interest
All authors must disclose any financial or non-financial interests, relationships, or activities that could influence, or reasonably be perceived to influence, the submitted work. Such interests may include employment, consultancies, honoraria, stock ownership, patents, advisory roles, paid expert testimony, personal or professional relationships, or other relevant affiliations. A separate Conflict of Interest statement is required in all submitted manuscripts. If no relevant conflicts exist, authors should include a clear statement such as: “The authors declare no conflicts of interest.” Disclosure of a conflict of interest does not automatically prevent publication, but failure to disclose a relevant conflict may lead to editorial action. Please refer to the Policies and Ethics page for additional details.3. Research Ethics, Ethics Approval, and Informed Consent
Research involving human participants, human tissue, identifiable personal data, animals, or other ethically sensitive materials must comply with applicable ethical, legal, and institutional requirements. Authors are responsible for obtaining all required approvals and consents before conducting and reporting the work.
For human or animal studies, authors must state in the Methods section and in the end-of-manuscript declarations the name of the approving ethics committee or Institutional Review Board, the approval number or identifier where available, and the date of approval. If approval was waived, exempted, or not required, this must be stated clearly together with a brief explanation.
For studies involving human participants, authors must state whether informed consent to participate was obtained and whether consent was oral or written. For minors or incapacitated participants, consent must be obtained from parents or legal guardians as appropriate.
For animal studies, authors must state the approving body and relevant approval details and must confirm that the work complied with applicable animal CARE and welfare requirements.
Where investigators do not have access to a formal ethics committee, research involving human participants must be conducted in accordance with recognized ethical principles such as the Declaration of Helsinki.
4. Reporting Guidelines and Trial Registration
Authors must follow the reporting guideline appropriate to the manuscript’s study design or article type. Reporting requirements help ensure that research is reported clearly, completely, and transparently. Authors should consult the Policies and Ethics page for additional details.
4.1. Randomized Controlled Trials and Clinical Trial Registration
All randomized controlled trials submitted for publication must include the appropriate CONSORT/">CONSORT materials, including a completed CONSORT/">CONSORT flow chart. Clinical trials must be registered in a public trials registry as a condition of consideration for publication. The manuscript must include the registry name and registration number. Purely observational studies, in which assignment of the intervention is not at the discretion of the investigator, do not require trial registration.
4.2. Case Reports
All case reports submitted to BioMedicine must follow the CARE reporting guideline. Authors must complete and submit the CARE Checklist and ensure that the case report is reported clearly, completely, and consistently.
4.3. Other Reporting Guidelines
Authors must follow the reporting guideline most appropriate to their study design. Examples include STROBE for observational studies, PRISMA for systematic reviews and meta-analyses, STARD for diagnostic accuracy studies, SPIRIT for study protocols, and ARRIVE for animal research. Authors are encouraged to consult the EQUATOR Network for guidance on selecting the appropriate reporting standard.
5. Consent for Publication and Patient Privacy
For any manuscript that includes case details, patient photographs, radiologic images, pedigrees, or other material from which an individual could potentially be identified, authors must obtain written informed consent for publication.
For case reports, consent for publication is required in all cases, regardless of whether the patient appears to be directly identifiable. This requirement reflects the journal’s commitment to protecting patient privacy and recognizing that identification may sometimes be possible even when names and direct identifiers have been removed.
Authors should retain the signed consent documentation and provide it to the journal upon request. Consent forms should not be uploaded or submitted unless specifically requested by the journal.
Names, initials, hospital numbers, and other direct identifiers should not be included unless scientifically necessary and supported by appropriate consent for publication. Even where consent has been obtained, identifying details should be minimized wherever possible.
6. Previous Publication, Duplicate Submission, and Related Manuscripts
Submitted manuscripts are considered with the understanding that they have not been published previously in print or electronic form, except in abstract or poster form or as a disclosed preprint, and that they are not under consideration in whole or in part by another journal or publication outlet. Authors should disclose any closely related manuscripts, prior postings, conference abstracts, preprints, or overlapping publications at the time of submission. Duplicate submission, redundant publication, and inappropriate text or data overlap are not permitted.7. Basic Criteria
Articles should be written in English using American English spelling and should meet the following basic criteria: the work is within the journal’s Aims and Scope; the material is original; the information is important; the writing is clear and concise; the study methods are appropriate; the data are valid; and the conclusions are reasonable and supported by the data.
8. Article Categories
8.1. Review Articles
Review articles should provide a balanced overview of an important and topical subject in the field and should critically assess the relevant literature and data sources. They should cover areas of consensus as well as areas that remain controversial or under active investigation. Review articles are by invitation only. Typical length: no more than 4000 words, 50–100 references.
Systematic reviews and meta-analyses must follow PRISMA. Relevant end-of-manuscript declarations must be included, including Funding, Conflict of Interest, Author Contributions, Data Availability for systematic reviews or meta-analyses involving generated or analyzed datasets, and an AI Use Declaration when substantive generative AI or AI-assisted technologies were used.
8.2. Original Articles
Original Articles may include randomized trials, intervention studies, studies of screening and diagnostic tests, laboratory and animal studies, cohort studies, cost-effectiveness analyses, case-control studies, and surveys with high response rates that make a new and significant contribution to the field.
Section headings should normally be: Abstract, Introduction, Methods, Results, Discussion, Acknowledgments (optional), Funding, Conflict of Interest, Author Contributions, Data Availability, Ethics Approval, Consent to Participate, Consent for Publication when identifiable personal information or potentially identifiable material is included, AI Use Declaration when substantive generative AI or AI-assisted technologies were used, and References. Typical length: no more than 5500 words, 40–80 references.
8.3. Case Reports
Case Reports are short discussions of a case or case series with unique features not previously described that make an important teaching point or scientific observation. They may describe novel techniques, novel use of equipment, or new information on diseases of importance.
Section headings should normally be: Abstract, Introduction, Case Report, Discussion, Acknowledgments (optional), Funding, Conflict of Interest, Author Contributions, Consent for Publication, Ethics Approval for cases involving research approval or ethics review, AI Use Declaration when substantive generative AI or AI-assisted technologies were used, and References.
All case reports must follow the CARE reporting guideline and must include consent for publication. Typical length: no more than 1500 words, 20–40 references.
8.4. Short Communications
Short Communications should be concise presentations of clinical or preliminary experimental results. Section headings should normally be: Abstract, Introduction, Methods, Results, Discussion, Acknowledgments (optional), Funding, Conflict of Interest, Author Contributions, Data Availability for Short Communications reporting original research, Ethics Approval for studies involving human participants, human data, human tissue, animals, or other ethically sensitive materials, Consent statements for studies involving human participants or potentially identifiable material, AI Use Declaration when substantive generative AI or AI-assisted technologies were used, and References. Typical length: no more than 1000 words, 20–40 references, with no more than four figures or tables. The Editors reserve the right to decide what constitutes a Short Communication.
8.5. Letters to the Editor
Letters are welcome in response to previously published articles and may also include interesting cases that do not meet the threshold for a full case report, as well as other communications of general interest. Letters should have a title, include appropriate references, and include the corresponding author’s mailing and email addresses. They may be sent for peer review at the discretion of the Editors. Typical length: no more than 600 words, 5–10 references; 1 table and/or 1 figure may be included.
Letters should include a Conflict of Interest statement and a Funding statement. An AI Use Declaration must also be included when substantive generative AI or AI-assisted technologies were used.
8.6. Editorials
Editorials are invited articles or comments concerning a specific paper in the journal or a topical issue in the field. While normally invited, unsolicited editorials may be submitted. Typical length: no more than 1500 words, 15–30 references.
Editorials should include a Conflict of Interest statement and a Funding statement. An AI Use Declaration must also be included when substantive generative AI or AI-assisted technologies were used.
9. Manuscript Preparation
Text should be typed double-spaced on one side of A4 paper, with outer margins of 2.5 cm. A manuscript should include a title page, abstract, main text, statements and declarations, references, and figures and tables as appropriate. Each section of the manuscript should begin on a new page. Pages should be numbered consecutively, beginning with the title page.
For initial submission, authors must prepare a blinded manuscript file and a separate title page file as described in Section 1.1. All required statements and declarations should appear in the final accepted manuscript for publication. During double-blind review, any author-identifying statement or declaration should be provided separately to preserve anonymity.
9.1. Title Page
The title page should contain the following information, in order from top to bottom:
- category of paper;
- article title;
- names spelled out in full of all authors and their affiliations, with superscripted lowercase letters linking authors to affiliations;
- corresponding author details, including name, email, mailing address, telephone, and fax numbers where available;
- acknowledgments or other author-identifying statements that should not appear in the blinded manuscript file.
The name of each author should be written with the family name last, for example, Jing-Lin Chang. Authorship is restricted to individuals who have contributed significantly to the work and who meet the journal’s authorship criteria.
9.2. Abstract and Keywords
Abstracts should be no more than 300 words in length. Abstracts for Original Articles should be structured, with the section headings: Background/Introduction, Purpose(s)/Aim(s), Methods, Results, and Conclusion. Abstracts for Case Reports are unstructured, but should include the significance and purpose of the case presentation, the diagnostic methods, the key data, and brief comments or suggestions regarding the case. Abstracts for Review Articles and Short Communications may also be unstructured. No abstract is required for Letters to the Editor and Editorials. For article categories requiring an abstract, 3–5 relevant keywords should also be provided in alphabetical order.
9.3. Main Text
The text for Original Articles should normally be organized into the following sections: Introduction, Methods, Results, and Discussion. Sections for Case Reports are: Introduction, Case Report, and Discussion. Each section should begin on a new page.
9.3.1. Abbreviations
Where a term or definition will be referred to repeatedly, it should be written in full when it first appears in the text, followed by the abbreviation in parentheses. Thereafter, the abbreviation may be used. An abbreviation should not be first defined in a section heading. Restrict the number of abbreviations to those that are absolutely necessary.9.3.2. Units
System International (SI) units should be used, with the exception of blood pressure values, which should be reported in mmHg. Use the metric system for the expression of length, area, mass, and volume. Temperatures should be given in degrees Celsius.
9.3.3. Names of Drugs, Devices, and Other Products
Use the Recommended International Nonproprietary Name for medicinal substances unless the specific trade name is directly relevant to the discussion. For devices and other products, the generic term should be used unless the trade name is directly relevant. If a trade name is used, provide the manufacturer name and city, state, and country at first mention.
9.3.4. Statistical Requirements
Statistical analysis is essential for all research papers except case reports. Use correct nomenclature of statistical methods. Descriptive statistics should follow the scale of measurement used in the study. Inferential statistics should be described in sufficient detail. All P values should be expressed to 2 digits to the right of the decimal point, unless P < 0.01, in which case 3 digits should be used. The smallest P value that should be expressed is P < 0.001; the largest is P > 0.99.
9.3.5. Personal Communications and Unpublished Data
Personal communications and unpublished data should not be included in the reference list but may be described in the text. Authors should provide the full name and highest academic degree of the source, the date of the communication, and whether it was oral or written. A signed statement of permission should be obtained from each person identified as a source of personal communication or unpublished data.
9.4. Statements and Declarations
Relevant statements and declarations must appear in a dedicated section near the end of the manuscript. Ethics-related information must be reported in the Methods section and must also be included again in the declarations for manuscripts involving human participants, human data, human tissue, animals, or other ethically sensitive materials. During initial double-blind review, any declaration that would identify the authors or their institutions must be provided separately, and all required statements must be restored in the final accepted manuscript for publication.
9.4.1. Acknowledgments
The Acknowledgments section is optional and may be used to recognize individuals, institutions, or organizations that contributed to the work but do not meet the journal’s criteria for authorship. The Acknowledgments section should not be used for formal declarations such as Funding, Conflict of Interest, Data Availability, or AI use disclosures. Individuals named in this section should have given permission to be acknowledged.
9.4.2. Funding
A separate Funding statement is required in all submitted manuscripts. The statement must identify the source or sources of support, including the name of the funding organization and grant number, project number, or other relevant funding identifier where available. Authors must also state the role of the funder in the work. If the funder had no role, this must be stated. If no external funding was received, authors must include a clear statement such as: “The authors received no funding for this work.”
9.4.3. Conflict of Interest
A separate Conflict of Interest statement is required in all submitted manuscripts. If no relevant conflicts exist, authors should include a clear statement such as: “The authors declare no conflicts of interest.” Both financial and non-financial interests should be disclosed where relevant.
9.4.4. Author Contributions
Original Articles, Review Articles, Case Reports, and Short Communications must include an Author Contributions statement. Letters and Editorials may include such a statement where appropriate. The statement should briefly describe each author’s role, for example study conception and design, data collection, analysis, interpretation, manuscript drafting, critical revision, supervision, or final approval.
Example: “Author A conceived the study. Author B collected the data. Authors A and C analyzed the data. Author A drafted the manuscript. All authors reviewed and approved the final version.”
9.4.5. Data Availability
A Data Availability Statement is required for all original research articles and for Short Communications reporting original research. The statement must explain whether the data are publicly available, available on reasonable request, restricted for ethical or legal reasons, or not applicable.
Examples: “The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.” “No new data were generated or analyzed in this study.”
9.4.6. Ethics Approval
For studies involving human participants, animals, human tissue, human data, or other ethically sensitive materials, authors must include an Ethics Approval statement identifying the approving committee or Institutional Review Board, the approval number or identifier where available, and the date of approval. If ethics approval was waived, exempted, or not required, this should be stated clearly together with a brief explanation.
Example: “This study was approved by [full name of ethics committee or IRB] (Approval No. [number], Date [date]).”
9.4.7. Consent to Participate
For studies involving human participants, authors must state whether informed consent to participate was obtained. Where consent was not required, the manuscript should explain why.
Example: “Written informed consent was obtained from all participants.”
9.4.8. Consent for Publication
Where identifiable personal information, case details, photographs, radiologic images, or other potentially identifiable material is included, authors must provide a separate statement confirming that informed consent for publication was obtained. For case reports, consent for publication is mandatory in all cases, regardless of whether the patient appears directly identifiable.
Example: “Written informed consent for publication was obtained from the patient.”
9.4.9. AI Use Declaration
Where generative AI or AI-assisted technologies have made a substantive contribution to the wording, content, or preparation of the manuscript, authors must include a separate AI Use Declaration at the end of the manuscript. This statement should identify the tool used, include the version where available, and describe the purpose and extent of its use.
Routine use of tools limited to spelling correction, grammar correction, formatting assistance, or reference management does not require formal disclosure, provided that such tools do not generate substantive new content.
AI tools may not be listed as authors or co-authors. Generative AI should not be used to create or alter scientific figures or images in ways that could misrepresent the underlying data or findings. If AI-based tools are used as part of the research methods, this should be described in the Methods section.
Example: “During the preparation of this manuscript, the authors used [tool name] ([version]) to improve language and readability. The authors reviewed and edited the output and take full responsibility for the content of the manuscript.”
9.5. References
References should be indicated by numbers in square brackets in line with the text and numbered consecutively in the order of appearance. References cited in tables or figure legends should be included in sequence at the point where the table or figure is first mentioned in the main text. Do not cite uncompleted work or work not yet accepted for publication as references. References should be limited to those cited in the text and listed in numerical order, not alphabetical order.
References should include, in order, author surnames and initials, article title, abbreviated journal name, year, volume, and inclusive page numbers. The last names and initials of all authors up to six should be included; where authors number seven or more, list the first six followed by “et al.” Authors are responsible for the accuracy and completeness of their references and for correct text citation.
Standard journal article Chen Z, Fan M, Bian Z, Zhang Q, Zhu Q, Lu P. Immunolocalization of heat shock protein 70 during reparative dentinogenesis. Chin J Dent Res 2000;3:50–5.
Journal supplement Kaplan NM. The endothelium as prognostic factor and therapeutic target: whatcriteria should we apply? J Cardiovasc Pharmacol 1998;32(Suppl 3):S78–80.
Journal article not in English but with English abstract Nakayama H, Ishikawa T, Yamashita S, Fukui I, Mutoh T, Hikichi K, et al. CSF leakage and anosmia in aneurysm clipping of anterior communicating artery by basal interhemispheric approach. No Shinkei Geka 2011;39:263–8. [In Japanese, English abstract]
Book Bradley EL. Medical and surgical management. Philadelphia: Saunders; 1982, p. 72–95.
Book chapter in book with editor and edition Greaves M, Culligan DJ. Blood and bone marrow. In: Underwood JCE, editor. General and systematic pathology. 4th ed. London: Churchill Livingstone; 2004, p. 615–72. Bulletin World Health Organization. World health report 2002: reducing risk, promoting healthy life. Geneva, Switzerland: World Health Organization; 2002.
Company/manufacturer publication/pamphlet Eastman Kodak Company, Eastman Organic Chemicals. Catalog no. 49. Rochester, NY: Eastman Kodak; 1977, p. 2–3.
Electronic publications Duchin JS. Can preparedness for biological terrorism save us from pertussis? Arch Pediatr Adolesc Med 2004;158:106–7. Available from: http://archpedi.amaassn. org/cgi/content/full/158/2/106. Accessed June 5, 2004.
Smeeth L, Iliffe S. Community screening for visual impairment in the elderly. Cochrane Database Syst Rev 2002(2):CD001054. doi:10.1002/14651858. CD1001054.
Items presented at a meeting but not yet published Durbin D, Kallan M, Elliott M, Arbogast K, Cornejo R, Winston F. Risk of injury to restrained children from passenger air bags. Paper presented at: 46th Annual Meeting of the Association for the Advancement for Automotive Medicine; September 2002; Tempe, AZ.
Greenspan A, Eerdekens M, Mahmoud R. Is there an increased rate of cerebrovascular events among dementia patients? Poster presented at: 24th Congress of the Collegium Internationale Neuro- Psychopharmacologicum (CINP); June 20–24, 2004; Paris, France.
Khuri FR, Lee JJ, Lippman SM. Isotretinoin effects on head and neck cancer recurrence and second primary tumors. In: Proceedings from the American Society of Clinical Oncology; May 31–June 3, 2003; Chicago, IL. Abstract 359.
Item presented at a meeting and published Cionni RJ. Color perception in patients with UV- or blue-light-filtering IOLs. In: Symposium on Cataract, IOL, and Refractive Surgery. San Diego, CA: American Society of Cataract and Refractive Surgery; 2004. Abstract 337.
Material accepted for publication but not yet published Carrau RL, Khidr A, Crawley JA, Hillson EM, Davis JK, Pashos CL. The impact of laryngopharyngeal reflux on patient-reported quality of life. Laryngoscope. In press. Ofri D. Incidental findings: Lessons from my patients in the art of medicine. Boston, MA: Beacon Press. In press.
Theses and dissertations Undeman C. Fully automatic segmentation of MRI brain images using probabilistic diffusion and a watershed scale-space approach [master’s thesis]. Stockholm, Sweden: NADA, Royal Institute of Technology; 2001.
Ayers AJ. Retention of resin restorations by means of enamel etching and by pins [dissertation]. Indianapolis: Indiana University; 1971.
Website American Association of Oral and Maxillofacial Surgeons. Wisdom teeth. AAOMS Web site. http://www.aaoms.org/wisdom_teeth.php. Published January 23, 2008. Updated March 9, 2009. Accessed November 15, 2009.
8.6. Tables
Tables should supplement, not duplicate, the text. They should have a concise table heading, be self explanatory, and numbered consecutively in the order of their citation in the text. Information requiring explanatory footnotes should be denoted using superscripted lowercase letters in alphabetical order (a, b, c, etc.). Asterisks (*, **) are used only to indicate the probability level of tests of significance. Abbreviations used in the table must be defined and placed after the footnotes. If you include a block of data or table from another source, whether published or unpublished, you must acknowledge the original source.
8.7. Figures
8.7.1. General guidelines
The number of figures should be restricted to the minimum necessary to support the textual material. They should have an informative figure legend and be numbered in the order of their citation in the text. All symbols and abbreviations should be defined in the legend. Patient identification should be obscured. All lettering should be done professionally and should be in proportion to the drawing, graph or photograph.
Photomicrographs must include an internal scale marker, and the legend should state the type of specimen, original magnification and stain.
Figures must be submitted as separate picture files at the correct resolution (see Section 9.7.2 below). The files should be named according to the figure number, e.g., "Article1_Fig1", "Article1_Fig2".
Figures must be submitted as separate picture files at the correct resolution (see Section 9.7.2 below). The files should be named according to the figure number, e.g., "Article1_Fig1", "Article1_Fig2".
Figures must accurately represent the original data. Any image adjustment must not misrepresent the underlying information and must be disclosed when image processing is relevant to interpretation of the figure. Generative AI must not be used to create, alter, enhance, or manipulate figures or images in a way that could misrepresent the underlying data or findings. Reproduced or adapted figures require appropriate credit and permission when the material is not original to the authors or is not covered by a license that permits the intended reuse.
9.7.2. Formats
When electronic artwork is finalized, please save or convert the images to one of the following formats: EPS for vector drawings; TIFF for color or grayscale photographs (minimum 300 dpi); TIFF for bitmapped line drawings (minimum 1000 dpi); TIFF for combination bitmapped line/half-tone images (minimum 600 dpi); or DOC, XLS, or PPT if created in those Microsoft Office applications. Do not supply files optimized only for screen use, files that are too low in resolution, or graphics that are disproportionately large for the content.
10. The Editorial and Peer Review Process
As a general rule, receipt of a manuscript will be acknowledged within 1 week of submission, and authors will be provided with a manuscript reference number for future correspondence. Submissions are reviewed by the Editorial Office to ensure that they contain all required parts and documents. Incomplete submissions may be returned without further consideration.
BioMedicine uses a double-blind peer review process. Authors must submit a blinded manuscript file and a separate title page file as described in Section 1.1. Manuscripts are forwarded to the Editor-in-Chief, who makes an initial assessment. If the manuscript does not appear to be of sufficient merit or is not appropriate for the journal, it may be rejected without external review. Manuscripts that appear suitable are normally reviewed by at least two qualified reviewers, who may include Editorial Board members or expert consultants assigned by the Editor-in-Chief.
Authors will usually be notified within approximately 6 weeks whether the submitted article is accepted, rejected, or subject to revision before acceptance, although delays may sometimes occur. Revised manuscripts may undergo further editorial assessment and, where appropriate, additional review.
11. Preparation for Publication
Once a manuscript has been accepted for publication, authors should submit the final version of the manuscript in MS Word format, with all tables and figures as applicable, to the Editorial Office. The final manuscript should include all required statements and declarations in their appropriate locations, including any information omitted from the blinded file during review.
Accepted manuscripts are copyedited according to the journal’s style, and PDF page proofs are emailed to the corresponding author for final approval. Authors are responsible for all statements made in their work, including changes made by the copy editor.
12. Publication Criteria
Submission to BioMedicine implies that the work has not been published previously in full, is not under consideration elsewhere, and has been approved by all listed authors.
BioMedicine may screen submitted manuscripts for plagiarism or text recycling using iThenticate. Similarity reports are used as part of editorial assessment, and editorial judgment is applied to evaluate the nature, extent, and context of any overlap. Concerns about originality, plagiarism, duplicate submission, redundant publication, text recycling, paper mills, or other publication-integrity matters may result in requests for clarification, revision, rejection, or post-publication action where necessary.
Authors are responsible for ensuring that their work is original, properly cited, and compliant with the journal’s ethical standards. Authors should consult the Policies and Ethics page for additional guidance on publication ethics, misconduct, conflicts of interest, reporting guidelines, AI use, third-party material, and related requirements.